Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05504356 · ClinicalTrials.gov registry record
Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation
A clinical trial of Atrial Fibrillation, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 1,125
- Enrollment target
- 1
- Study location
NCT05504356 is a study of Atrial Fibrillation that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 1,125 participants, below the 2,991-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05504356, a study of Atrial Fibrillation, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 1,125 participants
- Enrollment target
- 1
- Study location
Study Summary
VIBRANT-AF seeks to: * Identify clinically relevant predictors of effectiveness and complications of AF ablation procedures in a prospective, US-based, multi-center, real-world longitudinal study * Assess changes in modifiable lifestyle-related exposures influence the effectiveness of AF ablation * Determine incidence and predictors of complications of AF ablation procedures Participants will connect with the Eureka Research Platform and answer a series of surveys and activities over a one-year period. They will be asked about lifestyle habits, recurrence of AFib, hospitalizations, and general feelings and emotions.
Conditions Studied
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,125 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2027-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05504356
The ClinicalTrials.gov registry entry for NCT05504356 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,991-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (62% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.
NCT05504356 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05504356 about?
NCT05504356 is a clinical study titled "Volunteers to Investigate Best Results for Ablation and Novel Therapies for Atrial Fibrillation". VIBRANT-AF seeks to: * Identify clinically relevant predictors of effectiveness and complications of AF ablation procedures in a prospective, US-based, multi-center, real-world longitudinal study * Assess changes in modifiable lifestyle-related exposures influence the effectiveness of AF ablation *...
What is the current status of trial NCT05504356?
This trial is currently recruiting. The enrollment target is 1,125 participants. The study started on 2022-04-27. Estimated completion is 2027-07-31.
What conditions does trial NCT05504356 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
Who is sponsoring clinical trial NCT05504356?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05504356 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.